Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus
NCT00299871
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
542
Enrollment
INDUSTRY
Sponsor class
Conditions
Type 2 Diabetes
Interventions
DRUG:
LIXISENATIDE (AVE0010)
Sponsor
Sanofi